XTRA:DMPPharmaceuticals
Dermapharm Holding (XTRA:DMP) Reaffirms Revenue Guidance, Is The Stock A Bargain?
Dermapharm Holding (XTRA:DMP) reaffirmed its 2026 earnings guidance, projecting consolidated revenue between €1,182 million and €1,218 million. This provides investors with a fresh reference point for assessing the stock following the confirmation.
See our latest analysis for Dermapharm Holding.
The reaffirmed guidance comes after a period of solid momentum, with Dermapharm Holding’s share price delivering a 23.48% year to date share price return and a 37.18% total shareholder return over the...